[ad_1]
Batavia Biosciences collaboration PATH polio vaccines
Batavia Biosciences – PATH Collaborative Polio Vaccines
Biosciences Batavia
Leiden, July 4, 2019 – Today, Batavia Biosciences announces that it has received a $ 2.2 million top-up grant from PATH, a global organization dedicated to health equity, to develop and manufacture new Oral Polio Vaccine (OPVV). The project, funded by the Bill & Melinda Gates Foundation, aims to protect children worldwide from all types of polio.
Thanks to the tireless efforts of health organizations around the world, the global eradication of polio is now in sight. PATH and its partners are working to fill one of the last gaps in the spread of vaccine-derived poliovirus. The aim of the consortium is to develop new, more attenuated and safer vaccine candidates against the three poliovirus serotypes, in order to prevent transmission from one disease to another, while avoiding the same risk of infection. seeding of new poliomyelitis cases derived from the vaccine. Poliomyelitis vaccine (OPV). If clinical trials succeed, NPV candidates could be stored and used as a safer response to possible outbreaks after polio eradication.
In January of last year, Batavia Biosciences announced a partnership with PATH, in which Batavia was awarded a $ 4 million grant for the production of master virus seeds and working seeds for candidates. nOPV1, nOPV2 and nOPV3 vaccines. Following the positive results of this program, Batavia will now produce master and working virus seeds for the second VPNO and VPNV3 vaccine candidates at its GMP manufacturing facility in Leiden, the Netherlands. The new candidate vaccine strains have been developed by the National Institute for Standards and Biological Controls (NIBSC) in the UK, the US Center for Disease Control and Prevention (CDC) and the University of California at San Francisco (UCSF). Batavia Biosciences brings a wealth of experience in developing polio vaccines and works closely with Bio Farma, one of the world's leading OPV vaccine manufacturers in Indonesia, as part of the PATH-managed VPN consortium. It is expected that Bio Farma will receive these virus seeds for the final production of the nOPV1 and nOPV3 vaccines.
Chris Yallop, CSO of Batavia Biosciences, explains, "These new oral poliovirus vaccines have been developed with advanced technologies in order to provide safer and more effective vaccines that hopefully will protect people in the event of an emergency." Polio epidemic of vaccine origin. "
Menzo Havenga, CEO of Batavia Biosciences, added, "We are proud of this recognition and the opportunity to work with PATH and its partners to protect children around the world from this terrible disease."
About Batavia Biosciences
Batavia Biosciences significantly contributes to alleviating the human suffering caused by infectious diseases by improving the success rate of translating drug candidates from discovery to the clinic. We offer our innovative technologies and in-depth know-how to help our partners advance the preclinical phases of biopharmaceutical development at a faster pace, lower costs and increase success. The company focuses on the early stages of product development, including cell line generation, upstream process development (mammals and microbials), purification development, product characterization and clinical manufacturing. Headquartered in Leiden, the Netherlands, with a subsidiary in Woburn, Mbad., And offices in Hong Kong, Batavia Biosciences has the privilege of having strong strategic partners around the world.
www.bataviabiosciences.com
Contact for writers
Chris Yallop, CSO
[email protected]
+31889950600
-
Batavia Biosciences collaboration PATH polio vaccines
Source link
